Cognition Therapeutics Files 2024 10-K
Ticker: CGTX · Form: 10-K · Filed: Mar 20, 2025 · CIK: 1455365
| Field | Detail |
|---|---|
| Company | Cognition Therapeutics INC (CGTX) |
| Form Type | 10-K |
| Filed Date | Mar 20, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, financials, biotechnology
TL;DR
CGTX 2024 10-K filed. Financials for year ending Dec 31, 2024 out.
AI Summary
Cognition Therapeutics Inc. filed its 2024 10-K on March 20, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, focused on biological products, is based in Pittsburgh, PA, and operates under the SIC code 2836. Key financial data and operational details for the fiscal year 2024 are presented in this filing.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Cognition Therapeutics' financial health, operational performance, and strategic direction for the fiscal year 2024.
Risk Assessment
Risk Level: medium — As a biotechnology company, Cognition Therapeutics likely faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 59,854,877 — Total Assets (Reported for the fiscal year ending December 31, 2024.)
- 32,165,478 — Total Liabilities (Reported for the fiscal year ending December 31, 2024.)
- 544,000 — Common Stock Shares Outstanding (As of December 31, 2024.)
Key Players & Entities
- COGNITION THERAPEUTICS INC (company) — Filer
- 2024-12-31 (date) — Fiscal Year End
- 2025-03-20 (date) — Filing Date
- 2836 (number) — Standard Industrial Classification (SIC) code for Biological Products
- 412-481-2210 (phone_number) — Business Phone Number
FAQ
What were Cognition Therapeutics' total revenues for the fiscal year ended December 31, 2024?
The provided excerpt does not explicitly state the total revenues for the fiscal year ended December 31, 2024. It focuses on balance sheet items and equity transactions.
What is the company's primary business activity as indicated by its SIC code?
The company's SIC code is 2836, which corresponds to Biological Products (No Diagnostic Substances).
When was the 10-K filing submitted to the SEC?
The 10-K filing was submitted on March 20, 2025.
What are the company's principal executive offices located?
The company's business address is located at 2403 Sidney Street, Suite 261, Pittsburgh, PA 15203.
What types of equity financing activities are mentioned in relation to Additional Paid-In Capital?
The filing mentions 'AtMarketOffering', 'FollowOnPublicOffering', and 'EquityLineFinancing' as types of equity financing activities impacting Additional Paid-In Capital for the periods 2023 and 2024.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 20, 2025 regarding COGNITION THERAPEUTICS INC (CGTX).